JP6302896B2 - 心室性頻脈性不整脈イベントを処置するためまたはそのリスクを予測するための方法 - Google Patents

心室性頻脈性不整脈イベントを処置するためまたはそのリスクを予測するための方法 Download PDF

Info

Publication number
JP6302896B2
JP6302896B2 JP2015512902A JP2015512902A JP6302896B2 JP 6302896 B2 JP6302896 B2 JP 6302896B2 JP 2015512902 A JP2015512902 A JP 2015512902A JP 2015512902 A JP2015512902 A JP 2015512902A JP 6302896 B2 JP6302896 B2 JP 6302896B2
Authority
JP
Japan
Prior art keywords
level
soluble
subject
biological sample
additional biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015512902A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015520371A (ja
Inventor
ジェイムズ ブイ. スナイダー
ジェイムズ ブイ. スナイダー
ティモシー エドワード マイヤー
ティモシー エドワード マイヤー
クレイグ マイケル ストールン
クレイグ マイケル ストールン
ロバート ダブリュ. ゲルウィーン
ロバート ダブリュ. ゲルウィーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardiac Pacemakers Inc
Original Assignee
Cardiac Pacemakers Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiac Pacemakers Inc filed Critical Cardiac Pacemakers Inc
Publication of JP2015520371A publication Critical patent/JP2015520371A/ja
Application granted granted Critical
Publication of JP6302896B2 publication Critical patent/JP6302896B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/362—Heart stimulators
    • A61N1/3627—Heart stimulators for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/38—Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
    • A61N1/39—Heart defibrillators
    • A61N1/3956—Implantable devices for applying electric shocks to the heart, e.g. for cardioversion
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/326—Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Artificial Intelligence (AREA)
  • Medical Informatics (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Signal Processing (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
JP2015512902A 2012-05-18 2013-05-17 心室性頻脈性不整脈イベントを処置するためまたはそのリスクを予測するための方法 Expired - Fee Related JP6302896B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261649202P 2012-05-18 2012-05-18
US61/649,202 2012-05-18
PCT/US2013/041686 WO2013173778A1 (en) 2012-05-18 2013-05-17 Methods for treating or predicting risk of a ventricular tachyarrhythmia event

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018038175A Division JP6600709B2 (ja) 2012-05-18 2018-03-05 心室性頻脈性不整脈イベントを処置するためまたはそのリスクを予測するための方法

Publications (2)

Publication Number Publication Date
JP2015520371A JP2015520371A (ja) 2015-07-16
JP6302896B2 true JP6302896B2 (ja) 2018-03-28

Family

ID=49584355

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015512902A Expired - Fee Related JP6302896B2 (ja) 2012-05-18 2013-05-17 心室性頻脈性不整脈イベントを処置するためまたはそのリスクを予測するための方法
JP2018038175A Expired - Fee Related JP6600709B2 (ja) 2012-05-18 2018-03-05 心室性頻脈性不整脈イベントを処置するためまたはそのリスクを予測するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018038175A Expired - Fee Related JP6600709B2 (ja) 2012-05-18 2018-03-05 心室性頻脈性不整脈イベントを処置するためまたはそのリスクを予測するための方法

Country Status (11)

Country Link
US (3) US20130345805A1 (cg-RX-API-DMAC7.html)
EP (2) EP3434260A1 (cg-RX-API-DMAC7.html)
JP (2) JP6302896B2 (cg-RX-API-DMAC7.html)
CN (2) CN104507383B (cg-RX-API-DMAC7.html)
AU (2) AU2013262515B2 (cg-RX-API-DMAC7.html)
CA (1) CA2873896A1 (cg-RX-API-DMAC7.html)
ES (1) ES2709697T3 (cg-RX-API-DMAC7.html)
HK (1) HK1208624A1 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN09776A (cg-RX-API-DMAC7.html)
MX (1) MX357740B (cg-RX-API-DMAC7.html)
WO (1) WO2013173778A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
ES2375181T3 (es) 2002-05-09 2012-02-27 The Brigham And Women's Hospital, Inc. 1l 1rl-1 como un marcador de enfermedades cardiovasculares.
PL2386860T4 (pl) 2006-04-24 2015-09-30 Critical Care Diagnostics Inc Przewidywanie śmiertelności i wykrywanie poważnej choroby
ATE517341T1 (de) * 2006-04-27 2011-08-15 Critical Care Diagnostics Inc Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen
DK2482078T3 (en) 2006-05-01 2016-05-02 Critical Care Diagnostics Inc Cardiovascular disease diagnosis
PT3093663T (pt) 2008-04-18 2018-10-19 Critical Care Diagnostics Inc Previsão do risco de eventos cardíacos adversos maiores
RU2684724C2 (ru) 2010-04-09 2019-04-11 Критикал Кэа Дайэгностикс, Инк. Антитела против растворимого st-2 человека и способы анализа
CN103718046B (zh) 2011-03-17 2016-10-12 重症监护诊断股份有限公司 预测不良临床结果的风险的方法
PL2734222T3 (pl) 2011-07-18 2017-03-31 Critical Care Diagnostics, Inc. Sposoby leczenia chorób układu krążenia i prognozowania skuteczności terapii ruchowej
CN104136072B (zh) * 2012-01-31 2016-08-24 心脏起搏器公司 使用生物标记物组数据诊断心力衰竭的可植入装置和方法
CN104159638A (zh) 2012-01-31 2014-11-19 心脏起搏器公司 用于使用生物标记物组数据控制心脏再同步装置/疗法的系统和方法
AU2013262515B2 (en) * 2012-05-18 2018-03-15 Cardiac Pacemakers, Inc. Methods for treating or predicting risk of a ventricular tachyarrhythmia event
MX358541B (es) 2012-08-16 2018-08-24 Critical Care Diagnostics Inc Metodos para predecir el riesgo de desarrollar hipertension.
IN2015DN01767A (cg-RX-API-DMAC7.html) 2012-08-21 2015-05-29 Critical Care Diagnostics Inc
BR112017005730B1 (pt) 2014-09-26 2023-12-12 Somalogic Operating Co., Inc Método para triagem de um indivíduo quanto ao risco de um evento cardiovascular ou para predizer a probabilidade que um indivíduo tenha tal evento
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10188863B2 (en) 2015-02-26 2019-01-29 Medtronic, Inc. Therapy program selection for electrical stimulation therapy based on a volume of tissue activation
JP7009977B2 (ja) * 2017-12-25 2022-01-26 国立大学法人東海国立大学機構 被検体の血中vegf-aに関する測定値を用いた心疾患の重症度及び予後予測を行うための方法、装置及びコンピュータプログラム
WO2020097190A1 (en) * 2018-11-06 2020-05-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Method of personalized treatment for cardiomyopathy and heart failure and associated diseases by measuring edema and cachexia/sarcopenia
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12400762B2 (en) 2018-12-11 2025-08-26 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US12322100B2 (en) 2018-12-11 2025-06-03 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001070817A1 (en) 2000-03-21 2001-09-27 Medical & Biological Laboratories Co., Ltd. Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
ES2375181T3 (es) 2002-05-09 2012-02-27 The Brigham And Women's Hospital, Inc. 1l 1rl-1 como un marcador de enfermedades cardiovasculares.
US20050123451A1 (en) 2003-10-31 2005-06-09 Hiroshi Nomura System and apparatus for body fluid analysis using surface-textured optical materials
WO2005078452A1 (en) 2004-02-05 2005-08-25 Medtronic, Inc. Methods and apparatus for identifying patients at risk for life threatening arrhythmias
PL2386860T4 (pl) 2006-04-24 2015-09-30 Critical Care Diagnostics Inc Przewidywanie śmiertelności i wykrywanie poważnej choroby
ATE517341T1 (de) 2006-04-27 2011-08-15 Critical Care Diagnostics Inc Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen
DK2482078T3 (en) * 2006-05-01 2016-05-02 Critical Care Diagnostics Inc Cardiovascular disease diagnosis
SI2019965T1 (sl) 2006-05-02 2015-10-30 Critical Care Diagnostics, Inc. Diferencialna diagnoza med pljučno boleznijo in boleznijo srca in ožilja
EP1884777A1 (en) * 2006-08-04 2008-02-06 Medizinische Hochschule Hannover Means and methods for assessing the risk of cardiac interventions based on GDF-15
KR101245877B1 (ko) 2006-08-04 2013-03-20 메디치니쉐 호흐슐레 하노버 Gdf-15 를 바탕으로 한, 심장 중재의 위험도를 평가하는수단 및 방법
ATE533061T1 (de) * 2007-08-03 2011-11-15 Brahms Gmbh Verfahren zur diagnose bakterieller infektionen
WO2009036011A2 (en) * 2007-09-11 2009-03-19 The Department Of Veterans Affairs Markers for ventricular arrhythmia
EP2107377A1 (en) 2008-04-04 2009-10-07 BRAHMS Aktiengesellschaft Pro-endothelin-1 levels for the prediction of risk of tachyarrhytmic events
PT3093663T (pt) 2008-04-18 2018-10-19 Critical Care Diagnostics Inc Previsão do risco de eventos cardíacos adversos maiores
GB0818650D0 (en) * 2008-10-10 2008-11-19 Uni I Oslo Methods
EP3178846B1 (en) * 2010-02-17 2018-08-22 Cedars-Sinai Medical Center Novel phosphorylation of cardiac troponin i as a monitor for cardiac injury
RU2684724C2 (ru) 2010-04-09 2019-04-11 Критикал Кэа Дайэгностикс, Инк. Антитела против растворимого st-2 человека и способы анализа
CN103718046B (zh) 2011-03-17 2016-10-12 重症监护诊断股份有限公司 预测不良临床结果的风险的方法
PL2734222T3 (pl) 2011-07-18 2017-03-31 Critical Care Diagnostics, Inc. Sposoby leczenia chorób układu krążenia i prognozowania skuteczności terapii ruchowej
AU2013262515B2 (en) * 2012-05-18 2018-03-15 Cardiac Pacemakers, Inc. Methods for treating or predicting risk of a ventricular tachyarrhythmia event
MX358541B (es) 2012-08-16 2018-08-24 Critical Care Diagnostics Inc Metodos para predecir el riesgo de desarrollar hipertension.
IN2015DN01767A (cg-RX-API-DMAC7.html) 2012-08-21 2015-05-29 Critical Care Diagnostics Inc

Also Published As

Publication number Publication date
WO2013173778A1 (en) 2013-11-21
EP2849729A1 (en) 2015-03-25
US11340236B2 (en) 2022-05-24
CA2873896A1 (en) 2013-11-21
AU2018204145A1 (en) 2018-06-28
AU2013262515A1 (en) 2014-12-04
US20130345805A1 (en) 2013-12-26
US20190391162A1 (en) 2019-12-26
JP6600709B2 (ja) 2019-10-30
US10408845B2 (en) 2019-09-10
AU2013262515B2 (en) 2018-03-15
US20170146552A1 (en) 2017-05-25
CN104507383A (zh) 2015-04-08
JP2018119976A (ja) 2018-08-02
IN2014DN09776A (cg-RX-API-DMAC7.html) 2015-07-31
MX2014013995A (es) 2015-09-04
MX357740B (es) 2018-07-23
CN109212223A (zh) 2019-01-15
EP2849729B1 (en) 2018-11-14
ES2709697T3 (es) 2019-04-17
EP3434260A1 (en) 2019-01-30
CN104507383B (zh) 2018-08-28
EP2849729A4 (en) 2016-01-20
CN109212223B (zh) 2021-11-12
JP2015520371A (ja) 2015-07-16
HK1208624A1 (en) 2016-03-11

Similar Documents

Publication Publication Date Title
JP6600709B2 (ja) 心室性頻脈性不整脈イベントを処置するためまたはそのリスクを予測するための方法
JP6757757B2 (ja) 高血圧症を発症するリスクを予測するための方法
Beghini et al. 2024 update in heart failure
ES2750126T3 (es) Procedimientos de predicción del riesgo de un resultado clínico adverso
Marcus et al. Markers of inflammation before and after curative ablation of atrial flutter
HK1208075B (en) Methods for predicting risk of developing hypertension
HK1212022B (en) Methods for predicting risk of developing hypertension

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150423

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150520

AA91 Notification that invitation to amend document was cancelled

Free format text: JAPANESE INTERMEDIATE CODE: A971091

Effective date: 20150721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170323

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170921

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180305

R150 Certificate of patent or registration of utility model

Ref document number: 6302896

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees